TechMARK movers: Vodafone falls on SFR rumours

Reports that Vivendi will not be willing to pay any more than £6bn for Vodafone's 44% stake in the French mobile phone operator SFR has hit the mobile phone giant's share price. Vivendi owns the controlling stake in SFR. Vodafone is also talking to Verizon Communications about pooling certain operations in order to save billions of pounds. Drug developer Vernalis is set to benefit from Cell Therapeutics licensing the rights to tosedostat for the Americas. Vernalis licensed tosedostat to Chroma Therapeutics in 2003 and it has sub-licensed them to Cell. Vernalis will receive royalties on commercial sales. Cell will further develop tosedostat and progress phase III studies for the treatment of Acute Myeloid Leukemia (AML). The studies will start in the fourth quarter. FTSE TechMARK - Risers Torotrak (TRK) 31.00p +11.71%Antisoma (ASM) 2.70p +10.20%AEA Technology Group (AAT) 4.75p +8.57%Imagination Technologies Group (IMG) 465.40p +6.69%Pace (PIC) 171.90p +3.80%CSR (CSR) 378.40p +2.66%Vernalis (VER) 40.00p +2.56%Parity Group (PTY) 24.25p +1.04%E2V Technologies (E2V) 108.00p +0.93%Dialight (DIA) 700.00p +0.29%FTSE TechMARK - Fallers Asterand (ATD) 15.50p -6.06%XP Power Ltd. (DI) (XPP) 1,682.00p -3.89%Oxford Instruments (OXIG) 620.00p -3.73%Phytopharm (PYM) 7.40p -2.95%Optos (OPTS) 200.00p -2.79%Cable & Wireless Worldwide (CW.) 67.05p -2.47%DRS Data & Research Services (DRS) 20.50p -2.38%BATM Advanced Communications Ltd. (BVC) 20.50p -2.38%Xaar (XAR) 211.00p -1.86%Vodafone Group (VOD) 175.80p -1.73%